Rhys Evans’s journey from a vulnerable infant confined to a sterile environment to a functioning adult with a working immune system highlights the evolving promise of gene therapy. Diagnosed with severe combined immunodeficiency (SCID) in May 2001 at less than one year old, Evans was initially placed in isolation at Great Ormond Street Hospital (GOSH) in London to protect him from lethal infections his body could not fight. His condition, caused by a rare genetic mutation that prevented the production of crucial T-cells, left him with virtually no immune defenses.

At the time, treatment options were limited. Traditional approaches involved strict isolation and bone marrow transplants from compatible donors, a process fraught with difficulty, including the risk of infection and the challenge of finding suitable matches. Evans’s medical team proposed an innovative and experimental gene therapy: removing his bone marrow cells, inserting a healthy version of the faulty gene into each cell using a harmless virus as a vector, and then reinfusing them into his body. This approach would enable Evans to use his own cells as donors, bypassing the need to find a compatible external donor.

The decision to pursue gene therapy was daunting for Evans’s parents, Mark and Marie, due to the early-stage nature of the treatment and potential risks, including the possibility that the gene insertion could trigger cancer such as leukemia. The medical team, led by Professor Adrian Thrasher, was transparent about these uncertainties. Still, facing the alternative of a likely fatal outcome, the family chose to proceed.

Over the subsequent weeks, Evans’s immune system gradually showed signs of recovery. Crucially, natural killer cells—an early form of immune defense—emerged, signaling the treatment was working. Within months, Evans left isolation, gaining milestones such as swimming lessons and attending nursery, events recorded in his personal scrapbook. Although his immune system required ongoing monitoring and support, the therapy fundamentally transformed his life.

Evans’s treatment was part of an early trial involving ten children, one of whom developed leukemia but later survived. Now in his mid-twenties, Evans considers himself “95 percent normal” and leads an active life working in entertainment. He acknowledges the lasting imprint of his early experiences but emphasizes his ability to engage fully with the world, confident in his immune system’s function.

Since Evans’s pioneering treatment, genetic therapies have advanced significantly. More precise gene-editing techniques have emerged, some allowing direct treatment within the body rather than relying on extracted cells. In 2025, a gene therapy was successfully administered to treat a metabolic condition in a newborn’s liver, marking progress beyond bone marrow-based treatments. Regulators in the United Kingdom have also adapted approval processes to accelerate access to such therapies.

Public health officials have lauded gene therapy’s potential to transform lives, offering new hope to families affected by rare genetic diseases, which collectively impact approximately one in 20 people. Evans’s case serves as both a milestone and a symbol of this broader revolution in medicine, demonstrating the feasibility and promise of genetic cures that were once considered unimaginable.